Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 9, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,100,000 ordinary shares.
- Purchase Price: 1,326.11 pence per share.
- Total Treasury Shares Held: 103,253,000 shares following the transaction.
- Shares in Issue: 5,842,501,994 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 1,100,000 shares on August 9, 2005, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 1,100,000 share repurchase against the company's cash position in the most recent full financial report.
- Confirm the updated share count (5,842,501,994 in issue) against subsequent filings to ensure accuracy.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authorization.
- Check for any subsequent Form 6-K filings regarding further share repurchases or Treasury share management.